基于肥胖与肌量划分的人体成分类型与动脉硬化的关系研究

王耀羚; 戚本玲; 白丽娟; 刘丽华; 王瑞云; 刘赟; 贺林锋

doi:10.13201/j.issn.1001-1439.2020.10.007

基于肥胖与肌量划分的人体成分类型与动脉硬化的关系研究

- 华中科技大学同济医学院附属协和医院老年病科(武汉, 430022)
基金项目:
国家自然科学基金面上项目(No:81571373)

国家自然科学基金青年项目(No:81601217)

湖北省自然科学基金(No:2017CFB627)

武汉协和医院科学研究基金(No:2019)

详细信息

通讯作者: 戚本玲,E-mail:qibenlingok_2015@163.com

中图分类号: R592;R543.5

收稿日期: 2020-06-09

修回日期: 2020-07-06

The correlation of body composition types based on obesity and muscle mass and atherosclerosis

- Department of Geriatrics, Union Hospital of Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430022, China

More Information

Corresponding author: QI Benling, E-mail: qibenlingok_2015@163.com

Received Date: 09 June 2020

Revised Date: 06 July 2020

摘要

摘要: 目的:评价脂肪及肌量指标对于动脉硬化风险的预测及诊断效力。方法:收集2018年11月—2019年11月同时完成动脉弹性检测及人体成分分析的住院患者共1150例的临床资料。使用心-踝血管指数(CAVI)评价动脉弹性,并根据CAVI将患者分为动脉硬化组与非动脉硬化组。使用生物电阻抗(BIA)人体成分测量仪分析人体成分。根据人群年龄四分位数将患者归类为青年、中年、老年前期和老年;根据体脂率分类:肥胖与非肥胖;根据四肢骨骼肌指数(ASMI)分类:肌量减少与非肌量减少;根据肥胖联合肌量分类:非肥胖且非肌量减少、单纯肥胖、单纯肌量减少及肥胖合并肌量减少。比较各类型的人体成分指标及CAVI差异。使用Logistic回归评价各人体成分类型形成动脉硬化的风险。使用ROC曲线评价各人体成分指标或类型对动脉硬化的诊断效力。结果:单纯肥胖、单纯肌量减少和肥胖合并肌量减少对动脉硬化的OR分别为1.74(95%CI:1.31~2.33)、2.21(95%CI:1.34~3.58)和29.30(95%CI:5.15~550.23)。调整年龄后,仅肥胖合并肌量减少表现出对动脉硬化显著的高风险,OR为11.87(95%CI:1.80~235.22)。在人体成分指标中,体重和BMI在动脉硬化组显著低于非动脉硬化组,呈现“肥胖悖论”。内脏脂肪/脂肪具有诊断动脉硬化的良好效力,其ROC曲线下面积(AUC)为0.65(95%CI:0.61~0.69),显著高于BMI(AUC=0.59)、ASMI(AUC=0.59)和内脏脂肪(AUC=0.54)。联合年龄、ASMI和内脏脂肪/脂肪诊断动脉硬化的AUC为0.84(95%CI:0.82~0.87)。结论:肥胖并肌量减少是独立于年龄的动脉硬化高危风险类型,结合年龄、ASMI和内脏脂肪/脂肪是预测动脉硬化的优选方案。
- 肥胖 /
- 肌量减少 /
- 肥胖性肌少 /
- 动脉硬化 /
- 肥胖悖论
Abstract: Objective: To evaluate indicators including fat and muscle mass for predicting and diagnosing the risk of arteriosclerosis. Method: Data for a total of 1 150 inpatients who completed both the arterial elasticity test and body composition analysis from November 2018 to November 2019 were collected. All patients were evaluated for the degree of arteriosclerosis using the cardio-ankle vascular index(CAVI), and all patients were divided into arteriosclerosis and non-arteriosclerosis group based on CAVI. The body compositions were analyzed using the bioelectrical impedance(BIA) body composition measuring instrument. Then several types of patients were formed in parallel according to various criteria: the youth, the middle-aged, the persenile, and the elderly based on quartiles of population age; the obesity and non-obesity based on body fat percentage; the reduced and non-reduced muscle mass based on appendicular skeletal mass index(ASMI); and the non-obesity with non-muscle mass reduction, simple obesity, simple muscle mass reduction, and obesity with muscle mass reduction based on the combination of obesity and muscle mass reduction. The body composition indicators and CAVI among each type of groups were compared. Logistic regression analysis was used to evaluate the risk of atherosclerosis for each body composition type. The ROC curve was used to evaluate the diagnostic efficacy of body composition indicators and body composition types on atherosclerosis. Result: The OR of the type of simple obesity, simple muscle mass reduction, and obesity with muscle mass reduction to arteriosclerosis were 1.74(95%CI: 1.31-2.33), 2.21(95%CI: 1.34-3.58), and 29.30(95%CI: 5.15-550.23), respectively. After adjustment for the age, only the type of obesity with muscle mass reduction remained a significant risk for arteriosclerosis, with OR of 11.87(95%CI: 1.80-235.22). Among the body composition indicators, weight and BMI were significantly lower in the arteriosclerosis group than those in the non-arteriosclerosis group, and the difference of weight and BMI between the groups showed the "obesity paradox". Visceral fat/fat demonstrated high capability of diagnosing arteriosclerosis with AUC was 0.65(95%CI: 0.61-0.69), which was higher than BMI(AUC=0.59), ASMI(AUC=0.59) and visceral fat(AUC=0.54). The AUC for the diagnosis of arteriosclerosis utilizing age group, ASMI and visceral fat/fat together was 0.84(95%CI: 0.82-0.87).Conclusion: The body composition type of obesity with muscle mass reduction is an age-independent high-risk type of arteriosclerosis. The combination of age, ASMI, and visceral fat/fat is a better option for predicting arteriosclerosis.
- obesity /
- muscle mass reduction /
- obesity sarcopenia /
- arteriosclerosis /
- obesity paradox

HTML全文

参考文献(17)

[1]	Sattar N,Welsh P.The obesity paradox in secondary prevention:a weighty intervention or a wait for more evidence?[published online ahead of print,2020 May 27].Eur Heart J.2020;ehaa398.doi:10.1093/eurheartj/ehaa398
[2]	Rong YD,Bian AL,Hu HY,et al.A cross-sectional study of the relationships between different components of sarcopenia and brachial ankle pulse wave velocity in community-dwelling elderly[J].BMC Geriatr,2020,20(1):115.
[3]	Ponti F,Santoro A,Mercatelli D,et al.Aging and imaging assessment of body composition:from fat to facts[J].Front Endocrinol(Lausanne),2019,10:861.
[4]	Chen LK,Woo J,Assantachai P,et al.Asian Working Group for Sarcopenia:2019 Consensus Update on Sarcopenia Diagnosis and Treatment[J].J Am Med Dir Assoc,2020,21(3):300-307.e2.
[5]	El Bizri I,Batsis JA.Linking epidemiology and molecular mechanisms in sarcopenic obesity in populations[J].Proc Nutr Soc,2020:1-9.
[6]	Srikanthan P,Hevener AL,Karlamangla AS.Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia:findings from the National Health and Nutrition Examination Survey III[J].PLoS One,2010,5(5):e10805.
[7]	Li CW,Yu K,Shyh-Chang N,et al.Circulating factors associated with sarcopenia during ageing and after intensive lifestyle intervention[J].J Cachexia Sarcopenia Muscle,2019,10(3):586-600.
[8]	Payne GA,Borbouse L,Kumar S,et al.Epicardial perivascular adipose-derived leptin exacerbates coronary endothelial dysfunction in metabolic syndrome via a protein kinase C-beta pathway[J].Arterioscler Thromb Vasc Biol,2010,30(9):1711-1717.
[9]	Park SY,Kim KH,Seo KW,et al.Resistin derived from diabetic perivascular adipose tissue up-regulates vascular expression of osteopontin via the AP-1 signalling pathway[J].J Pathol,2014,232(1):87-97.
[10]	Wang P,Xu TY,Guan YF,et al.Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor:role of nicotinamide mononucleotide[J].Cardiovasc Res,2009,81(2):370-380.
[11]	Achari AE,Jain SK.Adiponectin,a Therapeutic Target for Obesity,Diabetes,and Endothelial Dysfunction[J].Int J Mol Sci,2017,18(6).
[12]	Uemura Y,Shibata R,Ohashi K,et al.Adipose-derived factor CTRP9 attenuates vascular smooth muscle cell proliferation and neointimal formation[J].FASEB J,2013,27(1):25-33.
[13]	Lin XL,He XL,Zeng JF,et al.FGF21 increases cholesterol efflux by upregulating ABCA1 through the ERK1/2-PPARγ-LXRα pathway in THP1 macrophage-derived foam cells[J].DNA Cell Biol,2014,33(8):514-521.
[14]	Kim JH,Cho JJ,Park YS.Relationship between sarcopenic obesity and cardiovascular disease risk as estimated by the Framingham risk score[J].J Korean Med Sci,2015,30(3):264-271.
[15]	Kim TN,Park MS,Lim KI,et al.Skeletal muscle mass to visceral fat area ratio is associated with metabolic syndrome and arterial stiffness:The Korean Sarcopenic Obesity Study(KSOS)[J].Diabetes Res Clin Pract,2011,93(2):285-291.
[16]	Shirai K,Song M,Suzuki J,et al.Contradictory effects of β1-and α1-aderenergic receptor blockers on cardio-ankle vascular stiffness index(CAVI)--CAVI independent of blood pressure[J].J Atheroscler Thromb,2011,18(1):49-55.
[17]	Lee MM,Jebb SA,Oke J,et al.Reference values for skeletal muscle mass and fat mass measured by bioelectrical impedance in 390 565 UK adults[J].J Cachexia Sarcopenia Muscle,2020,11(2):487-496.